Construction and characterization of a new chimeric antibody against HER2

Abstract

Event Abstract Back to Event Construction and characterization of a new chimeric antibody against HER2 Mohammad M. Amiri1, Fazel Shokri1, 2*, Mahmood Jeddi-Tehrani2, Tohid Kazemi3, Motahhare Bahadori2, Mahshid Maddah2, Mohammad Hojjat-Farsanghi4, Jalal Khoshnoodi1 and Hodjatallah Rabbani2 1 Tehran University of Medical Sciences, Department of Immunology, School of Public Health, Iran 2 Avicenna Research Institute, ACECR, Monoclonal Antibody Research Center, Iran 3 Tabriz University of Medical Sciences, Department of Immunology, Faculty of medicine, Iran 4 Cancer Center Karolinska, Karolinska Hospital, Immune and Gene Therapy Lab, Sweden Aims HER2 proto-oncogene encodes a receptor tyrosine kinase overexpressed in a variety of solid tumors. Amplification of this gene has been shown to correlate with poor prognosis in breast cancer patients. Immunotherapy with anti-HER2 antibody has shown promising results in patients with HER2-positive breast cancer. We have recently reported characterization of a mouse monoclonal antibody (mAb) (1T0) directed against HER2, which binds to an epitope different from that recognized by Trastuzumab and specifically inhibits proliferation of tumor cells overexpressing HER2. In the present study, we report chimerization of this antibody. Materials and Methods The immunoglobulin variable region heavy (VH) and light (VL) chain genes of 1T0 hybridoma cells were amplified and inserted into a mammalian expression vector containing cDNA of human gamma-1 and kappa constant regions using Splice Overlap Extension (SOE) PCR. The construct was subsequently transfected in the mammalian CHO cell line and the chimeric antibody was expressed, purified and characterized by ELISA, Western blot and flow cytometry. Results The purified chimeric antibody specifically binds to recombinant HER2 and HER2 positive tumor cells. Binding of this antibody to tumor cells inhibited proliferation of these cells. The binding affinity of the chimeric mAb was comparable to the parental mouse mAb. Conclusion This chimeric anti-HER2 mAb is potentially a valuable tool for targeted immunotherapy of HER2 positive malignancies. Keywords: Chimeric antibody, breast cancer, HER2, Monoclonal antibody, Immunotherapy Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Adaptive Immunity Citation: Amiri MM, Shokri F, Jeddi-Tehrani M, Kazemi T, Bahadori M, Maddah M, Hojjat-Farsanghi M, Khoshnoodi J and Rabbani H (2013). Construction and characterization of a new chimeric antibody against HER2 . Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00069 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 08 Mar 2013; Published Online: 22 Aug 2013. * Correspondence: Prof. Fazel Shokri, Avicenna Research Institute, ACECR, Monoclonal Antibody Research Center, Tehran, Iran, fazshok@yahoo.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Mohammad M Amiri Fazel Shokri Mahmood Jeddi-Tehrani Tohid Kazemi Motahhare Bahadori Mahshid Maddah Mohammad Hojjat-Farsanghi Jalal Khoshnoodi Hodjatallah Rabbani Google Mohammad M Amiri Fazel Shokri Mahmood Jeddi-Tehrani Tohid Kazemi Motahhare Bahadori Mahshid Maddah Mohammad Hojjat-Farsanghi Jalal Khoshnoodi Hodjatallah Rabbani Google Scholar Mohammad M Amiri Fazel Shokri Mahmood Jeddi-Tehrani Tohid Kazemi Motahhare Bahadori Mahshid Maddah Mohammad Hojjat-Farsanghi Jalal Khoshnoodi Hodjatallah Rabbani PubMed Mohammad M Amiri Fazel Shokri Mahmood Jeddi-Tehrani Tohid Kazemi Motahhare Bahadori Mahshid Maddah Mohammad Hojjat-Farsanghi Jalal Khoshnoodi Hodjatallah Rabbani Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.